Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • Lugalbanda
    Junior Member
    • Oct 2016
    • 3

    #1

    DESeq factor design, and optimal number of samples

    For the 1st question, I want to know if I should run a single factor or double factor. These samples are match normal/tumor from different patients so something like this

    p1N p1T p2N p2T p3N p3T

    do i have to run a double factor run like this:

    ------------condition---------patientNumber
    ------------<factor>--------- <factor>
    p1N--------normal------------ 1
    p1T----------tumor ------------1
    p2N---------normal-------------2
    p2T----------tumor--------------2
    p3N--------normal-------------3
    p3T---------tumor--------------3


    or a single factor like this:

    -------------Condition
    -------------<factor>
    p1N--------normal
    p1T---------tumor
    p2N--------normal
    p2T---------tumor
    p3N--------normal
    p3T---------tumor


    I suppose the question boils down to whether or not DESeq cares if samples come from different patients.

    For the 2nd question, I have a thousand match normal/tumor from the same type of tissue but from different patients, should I run DESeq on all one thousand of them or is it fine to do a smaller amount like one hundred?
    Last edited by Lugalbanda; 10-05-2016, 01:53 PM. Reason: formatting
  • dpryan
    Devon Ryan
    • Jul 2011
    • 3478

    #2
    If you have tumour/normal pairs, then you should include the pairing information

    Code:
    design = ~patientNumber + condition
    DESeq2 (there's no reason to use DESeq) can get rather slow with 1000 samples. You'd be better with limma in that case.

    Comment

    • SylvainL
      Senior Member
      • Feb 2012
      • 180

      #3
      Hi dpryan,

      how slow for 1000 samples?

      Comment

      • dpryan
        Devon Ryan
        • Jul 2011
        • 3478

        #4
        @SylvainL: Good question and I don't know the answer to that. Perhaps Mike Love will pop by the thread and give a guesstimate.

        Comment

        • fanli
          Senior Member
          • Jul 2014
          • 197

          #5
          It seems from the cancer literature that most/all studies using a paired tumor-normal design only have one sample from each (e.g. p1T, p1N) and not in replicate (e.g. p1Ta, p1Tb, p1Tc, p1Na, p1Nb, p1Nc). Is that appropriate, or would it be better to do things in triplicate? Say by splitting a tumor sample into 3 sections?

          Comment

          • SylvainL
            Senior Member
            • Feb 2012
            • 180

            #6
            Your replicates are paired (p1T, p1N, p2T, p2N, etc...) so there is no need to split.

            Comment

            Latest Articles

            Collapse

            • SEQadmin2
              Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
              by SEQadmin2



              CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

              Despite this, “CRISPR helped turn genome editing from a specialized technique into
              ...
              07-31-2026, 11:01 AM
            • SEQadmin2
              Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
              by SEQadmin2


              Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

              The systematic characterization of the human proteome has
              ...
              07-20-2026, 11:48 AM
            • SEQadmin2
              Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
              by SEQadmin2



              Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
              ...
              07-09-2026, 11:10 AM

            ad_right_rmr

            Collapse

            News

            Collapse

            Topics Statistics Last Post
            Started by SEQadmin2, 08-03-2026, 10:13 AM
            0 responses
            18 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 07-31-2026, 02:55 AM
            0 responses
            33 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 07-24-2026, 12:17 PM
            0 responses
            23 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 07-23-2026, 11:41 AM
            0 responses
            21 views
            0 reactions
            Last Post SEQadmin2  
            Working...